Pharmaxis CEO Gary Phillips chats with Proactive’s Andrew Scott about promising interim data from a clinical trial assessing the use of topical anti-scarring drug PXS-6302 which he says has demonstrated high levels of enzyme inhibition and changes in biomarkers implicated in skin scarring. The study is being conducted under the leadership of director of the Western Australia Burns Service at the University of Western Australia (UWA), Professor Fiona Wood AM. Phillips discusses the study design and the types of patients that will be treated.
Pharmaxis CEO talks promising interim data from skin scarring study
